… for COVID-19–associated acute respiratory distress syndrome and chronic end-stage lung
diseases (non–COVID-19… with COVID-19–associated acute respiratory distress syndrome and …

… However, with COVID-19, concerns have been raised about high … as reported in early
COVID-19 epidemiological studies. … We encourage authors of future COVID-19 reports to provide …

… and could also be exploited in acute lung injury with hypoxia. Considering these hypotheses,
a COVID-19 patient with unresponsive respiratory failure was treated with adenosine for …

… COVID-19, refractory hypoxemia is common among the critically ill with acute respiratory
distress syndrome (ARDS… further complicated by respiratory and circulatory failure. This difficult …

… COVID-19 have a form of injury that is encompassed by the conceptual model of acute respiratory
distress syndrome (ARDS)… in patients with COVID-19-associated ARDS (41 mL/cm H 2 …

… While COVID‐19 overall mortality likely ranges from 1% to 5%, this is much higher in patients
with COVID‐19–induced acute respiratory distress syndrome (ARDS) (22%‐64%).3., 4., 7. …

… could have a place in the treatment of severe COVID-19 and, if so, what the optimal timing for
… patient with a persistently positive severe acute respiratory syndrome coronavirus 2 (SARS-…

… Information from critically ill coronavirus disease 2019 (COVID-19) … to characterize acute
respiratory distress syndrome (ARDS) … In conclusion, COVID-19 ARDS patient management has …

… compare sedative use between patients with COVID-19 ARDS and non-COVID-19 ARDS. …
for patients with known COVID-19-related acute respiratory distress syndrome (ARDS). B. …

… The potential benefits of mesenchymal stromal cell (MSC) therapy for patients with COVID-19
acute respiratory distress syndrome support the rapid commencement of clinical trials, as …